Last reviewed · How we verify
Combination of chemotherapy and immunotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Combination of chemotherapy and immunotherapy (Combination of chemotherapy and immunotherapy) — Guangzhou University of Traditional Chinese Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Combination of chemotherapy and immunotherapy TARGET | Combination of chemotherapy and immunotherapy | Guangzhou University of Traditional Chinese Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Combination of chemotherapy and immunotherapy CI watch — RSS
- Combination of chemotherapy and immunotherapy CI watch — Atom
- Combination of chemotherapy and immunotherapy CI watch — JSON
- Combination of chemotherapy and immunotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Combination of chemotherapy and immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-of-chemotherapy-and-immunotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab